ALLIANCE PHARMA PLC

M&A Activity • Feb 2, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7700D

Alliance Pharma PLC

02 February 2015

For immediate release	2 February 2015

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Acquisition of MacuVision

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce that its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired MacuVision Europe Limited ("MacuVision") for initial consideration of £5.5 million plus the net asset value of MacuVision at completion (estimated at £nil) and deferred contingent consideration of up to £6.0 million.  MacuVision sells MacuShield, an eye care treatment designed to be taken by sufferers of dry age-related macular degeneration and other eye conditions.

In the twelve months to 31 March 2014 the turnover of Solihull-based MacuVision was £2.7 million and the EBITDA (earnings before interest, tax, depreciation and amortisation) was £0.9 million.  In the twelve months to 31 December 2014, MacuShield sales were £3.4 million. As at 31 March 2014 MacuVision had net assets of £0.5 million.

MacuShield is a once-a-day capsule that contains meso-zeaxanthin, lutein and zeaxanthin - three carotenoids, or pigments. These three carotenoids are naturally present in the eye, where together they are known as macular pigment.

Macular pigment helps to protect the eye by neutralising free radicals and absorbing blue light, which can damage the retina. With age, and particularly in dry age-related macular degeneration and other eye conditions, the level of macular pigment is reduced creating the need for a dietary supplement to boost the level of pigment in the retina.

Around 75% of the MacuShield sales are generated in the UK, with the remainder being sales to international distributors, mainly in Europe.  Further details about MacuShield are available at this link: www.macushield.co.uk.

The initial consideration is being funded from existing cash and bank facilities, including a £5.5 million drawdown from the Group's £25 million Revolving Credit Facility ("RCF"). This brings the utilisation of the RCF to £6.8 million.  The deferred contingent consideration will be funded from cash generation and existing bank facilities.  Up to £4.0 million of this will be payable after one year and up to £2.0m will be payable after two years, both dependent on the revenue growth of MacuShield.

Key marketing staff will transfer to Alliance from MacuVision and the founders, Trevor and Anne McCormack, will continue their involvement in the business for twelve months.

Commenting on the acquisition, John Dawson, Alliance Pharma's Chief Executive, said: "We are delighted to start the year with this important acquisition, which brings both an immediate improvement in earnings and the potential of strong organic growth."

For further information:

### Alliance Pharma plc	### + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
### Buchanan	### + 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQLLFELFAIFIIE